Cyclopamine

目录号:S1146 别名: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。

规格 价格 库存 购买数量  
RMB 1227.56 现货
RMB 2188.93 现货
RMB 3037.37 现货
RMB 3833.48 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献17篇:

客户使用该产品的5个实验数据:

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Cyclopamine是一种特异性Hedgehog (Hh)信号通路拮抗剂,作用于Smoothened (Smo),在TM3Hh12细胞中IC50为46 nM。
靶点
Smoothened [1]
(TM3Hh12 cells)
46 nM
体外研究

Cyclopamine 抑制Hedgehog信号通路, IC50 为46 nM, 且在[3H]Hh-Ag结合实验中,作用于CHO-K1细胞,抑制人类Smo受体活性,IC50为 280 nM。[1] Cyclopamine作用于表达Patched (PTCH) mRNA的肠源性肿瘤细胞,显著抑制 Hedgehog通路活性,这种作用存在剂量依赖性,且浓度为3 μM时,抑制肿瘤细胞生长,抑制达75-95%, 但是作用于不表达PTCH mRNA的结肠癌细胞没有效果,说明Cyclopamine 特定作用于Hedgehog 通路,且没有毒性。[2]通过与Smo直接作用而抑制Hedgehog信号,Cyclopamine (10 μM) 抑制SMOhigh Cyclopamine-反应细胞系L3.6sl和 Panc 05.04增殖,抑制达 75-80%,且使凋亡率提高2.5到 3.5倍,但是不影响BxPC3-SMOlow 细胞系。[3] Cyclopamine 处理E3LZ10.7细胞系,显著降低Snail mRNA,且提供E-钙粘着蛋白转录。Cyclopamine处理Hedgehog依赖型 L3.6pl 细胞,显著抑制浸润型细胞, 使转移细胞降低500多倍,但是对Hedgehog非依赖性细胞系Panc-1没有影响。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 M{S1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fo[WlEPTB;NT64OlY3KM7:TR?= M3HPPXNCVkeHUh?=
DOHH-2 NEHueIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[4TJB1UUN3ME25MlM2Pjh7IN88US=> MmnFV2FPT0WU
no-10 NF;hTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7yTWM2OD17LkmwN|kh|ryP NWmyfFNjW0GQR1XS
LS-513 NU\3Z3UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGzb5lKUUN3ME2xNU4{PTR5IN88US=> NHfG[lZUSU6JRWK=
ALL-PO Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS5fWV3UUN3ME2xNU44PzN2IN88US=> NXXIc4xoW0GQR1XS
8-MG-BA NHvBVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF|LkGxNlMh|ryP NFn5cnBUSU6JRWK=
RPMI-8402 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzNZ49KSzVyPUG1Mlg2OzdizszN M3nTc3NCVkeHUh?=
EoL-1-cell MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO2TWM2OD1zOD61PVQ5KM7:TR?= MWTTRW5ITVJ?
NALM-6 NGDyT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF7LkCxOlch|ryP NYPuWGt1W0GQR1XS
DEL M1zET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHoNmNKSzVyPUKwMlE1PzFizszN MUfTRW5ITVJ?
SR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ|Lk[3NVUh|ryP MWnTRW5ITVJ?
697 NIHNSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7m[WpKSzVyPUK2MlYyPTVizszN MYTTRW5ITVJ?
COLO-829 NYSwO3F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r0UmlEPTB;Mk[uPFQ5OyEQvF2= MXvTRW5ITVJ?
EVSA-T MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTvTWM2OD1{Nz61OVYyKM7:TR?= MkWyV2FPT0WU
ATN-1 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHsdXRKSzVyPUOxMlI{OjlizszN MmXnV2FPT0WU
L-363 M2rnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPFTWM2OD1|MT63OFYyKM7:TR?= Mm\EV2FPT0WU
LAMA-84 NWLZSppHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LMW2lEPTB;M{KuOVIyOSEQvF2= MnS5V2FPT0WU
NOS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTN2LkK5OVYh|ryP MX\TRW5ITVJ?
BB30-HNC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTHb2I1UUN3ME2zOE4{OzB4IN88US=> NUi0[GdzW0GQR1XS
BC-1 Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfZbZJiUUN3ME2zO{46PzR4IN88US=> MlLlV2FPT0WU
IST-SL2 NEPpelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7qTWM2OD1|OD6yNlQh|ryP M37JVHNCVkeHUh?=
D-392MG NETSOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTRyLkKyNVUh|ryP NI\5d3FUSU6JRWK=
no-11 M1Xzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz2TWM2OD12MD61OVIyKM7:TR?= M3zPXXNCVkeHUh?=
LC4-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHwVml2UUN3ME20NE45PzF4IN88US=> M4n3XHNCVkeHUh?=
A388 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfXb246UUN3ME20Nk42QDR6IN88US=> MWfTRW5ITVJ?
NTERA-S-cl-D1 M2LteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;JTWM2OD12Mj63NFc1KM7:TR?= NWfEWYRqW0GQR1XS
CESS MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTNTWM2OD12ND6yNlMzKM7:TR?= MkC0V2FPT0WU
RS4-11 M2TnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHxfFBKSzVyPUS5MlA6OzhizszN MUDTRW5ITVJ?
MS-1 NH;LXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XjeWlEPTB;NUCuPVM2OSEQvF2= MYnTRW5ITVJ?
CTV-1 M{nMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfKWWxKSzVyPUWxMlA4PCEQvF2= NU\PTGprW0GQR1XS
D-502MG MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LsNWlEPTB;NUGuOlI4OSEQvF2= MoTjV2FPT0WU
ML-2 NYi0fohDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj2TWM2OD13Mj65NVk2KM7:TR?= MWDTRW5ITVJ?
SK-NEP-1 NEDaWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fpfWlEPTB;NUOuN|kzOyEQvF2= NFPTZ5NUSU6JRWK=
LOXIMVI Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTV|LkW4PFQh|ryP M3;UXXNCVkeHUh?=
DJM-1 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTMW3pDUUN3ME21Ok4{OzlzIN88US=> M2DXWHNCVkeHUh?=
GI-1 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLuPGhKSzVyPUW2MlYyPDlizszN MnjxV2FPT0WU
IST-MES1 NI\BWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ibmlEPTB;NkCuOVQ6OyEQvF2= NYTlfI5VW0GQR1XS
MV-4-11 M3rMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\WTWM2OD14MD62OVM5KM7:TR?= NHTuV2ZUSU6JRWK=
OVCAR-4 M37lTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL5TnY{UUN3ME22N{42PjV5IN88US=> NIe3PWpUSU6JRWK=
KE-37 M{X4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHzW4ExUUN3ME22Ok4zPjZ6IN88US=> NFzwd3JUSU6JRWK=
D-542MG M3rXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTiTWM2OD14OD60NVM2KM7:TR?= NX7TTJVlW0GQR1XS
MHH-PREB-1 M1XXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTd{Lki0OFEh|ryP MVTTRW5ITVJ?
MRK-nu-1 NEXUWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTd|LkS3NFUh|ryP M2HHVnNCVkeHUh?=
D-247MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPDWHZKSzVyPUezMlU1PDJizszN NF\keVNUSU6JRWK=
OCI-AML2 M{XB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS4bIhKSzVyPUe2Mlk{PjlizszN M4nSPXNCVkeHUh?=
LP-1 M4DsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[3c2lEPTB;OEKuPFc{OSEQvF2= NVnvcoE3W0GQR1XS
HCC1599 NHfPWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXDTWM2OD16ND6yPFM4KM7:TR?= M1noV3NCVkeHUh?=
KARPAS-45 M17JdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTh2Lk[5PVIh|ryP MXXTRW5ITVJ?
BE-13 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TPPWlEPTB;OUmuNFQ4PyEQvF2= MkTvV2FPT0WU
GCIY NXTqdVNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPKTWM2OD17OT6wPVU1KM7:TR?= MlrnV2FPT0WU
BV-173 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S2T2lEPTB;MUCwMlMzPSEQvF2= NXjneoxlW0GQR1XS
LB2518-MEL NGi5d|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnr[JhKSzVyPUGwNE44QDlizszN MkPTV2FPT0WU
KS-1 NFPTXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFyMT62N|kh|ryP MoHvV2FPT0WU
MOLT-16 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPxW4hPUUN3ME2xNFQvQTh4IN88US=> NYjMbWc1W0GQR1XS
NCI-H1770 M1zXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn5b4FKSzVyPUGwPE44QDRizszN NWq2O|d5W0GQR1XS
NCI-H82 NIDJPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHqeppyUUN3ME2xNVAvQTd4IN88US=> MX3TRW5ITVJ?
NCCIT Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLONYxMUUN3ME2xNVIvPTJ7IN88US=> MW\TRW5ITVJ?
KALS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDJTWM2OD1zMUWuPVQyKM7:TR?= NXO3dGMzW0GQR1XS
LB2241-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3sb5ZYUUN3ME2xNVYvPjd7IN88US=> MU\TRW5ITVJ?
HH MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTOTWM2OD1zMUeuN|k2KM7:TR?= NYP6b4d5W0GQR1XS
HD-MY-Z NV;4eWZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFzOD60PFgh|ryP MU\TRW5ITVJ?
EB-3 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPnc5RjUUN3ME2xNlMvODl2IN88US=> M{XXVHNCVkeHUh?=
BL-70 NI\jNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlraTWM2OD1zMkOuNVI4KM7:TR?= NY\mXnRTW0GQR1XS
K-562 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILLOpRKSzVyPUGyOk4zPDVizszN NX\BZop{W0GQR1XS
HT-144 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULyT|hHUUN3ME2xN|MvOTZ2IN88US=> NFjXRZRUSU6JRWK=
PF-382 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzLOpNEUUN3ME2xN|QvOzZzIN88US=> NGrCSGZUSU6JRWK=
RPMI-8226 M3;nb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD1zM{WuNFQ2KM7:TR?= NHX1OolUSU6JRWK=
NCI-H1355 M3G2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL3TWM2OD1zM{WuOVg4KM7:TR?= NX7LWod3W0GQR1XS
LXF-289 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF|OT63PFEh|ryP M2HsbHNCVkeHUh?=
NCI-H69 M1e3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3NcWVKSzVyPUG0Nk46OzJizszN MlvHV2FPT0WU
SK-MEL-1 NFfBT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3Re4xKSzVyPUG0O{4yOyEQvF2= MUDTRW5ITVJ?
KARPAS-299 NGnyd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrYcYFsUUN3ME2xOFkvOTJizszN MkLwV2FPT0WU
GB-1 NInZZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonrTWM2OD1zNEmuN|IzKM7:TR?= NX;XR4liW0GQR1XS
CMK NXryfWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fEXGlEPTB;MUS5MlUyPSEQvF2= M4PsPHNCVkeHUh?=
MPP-89 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH24N|FKSzVyPUG1Ok4xOzVizszN NFXXOmxUSU6JRWK=
KU812 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7kTWM2OD1zNkGuPVAzKM7:TR?= M2i1SXNCVkeHUh?=
REH NIPXSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfrTWM2OD1zNkKuNVI2KM7:TR?= M1vBR3NCVkeHUh?=
NEC8 NI\rWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\tPHBGUUN3ME2xOlUvODJ4IN88US=> NVLxR3E6W0GQR1XS
KP-N-YS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfyV41LUUN3ME2xOlgvOzl3IN88US=> Mn\RV2FPT0WU
Ramos-2G6-4C10 M1yycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGzdVNKSzVyPUG2PU46OTVizszN NYOz[FE5W0GQR1XS
Becker MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG4T5czUUN3ME2xO|QvOThizszN NWrVe5FEW0GQR1XS
LB647-SCLC NXzCe5JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKyT2FKSzVyPUG3OU45PDVizszN NXTsNFlQW0GQR1XS
LU-139 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfoV|VKSzVyPUG3PE4xOTlizszN MkXyV2FPT0WU
QIMR-WIL Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF5OT62OFYh|ryP NGDSb3NUSU6JRWK=
NCI-H1395 MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXD[o5KSzVyPUG3PU46QTZizszN M{fqWHNCVkeHUh?=
NOMO-1 Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[5c2lEPTB;MUiyMlg2KM7:TR?= NYfKflJnW0GQR1XS
GI-ME-N M2rUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES3PXVKSzVyPUG4O{46PjlizszN NYjNeVAxW0GQR1XS
KMS-12-PE M{LpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\VemlEPTB;MUi5MlI4OyEQvF2= NF7kS3FUSU6JRWK=
Daudi M3LnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hk[2lEPTB;MUmxMlEzQCEQvF2= NV7LWoo5W0GQR1XS
LB996-RCC NHHlU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnkWIFSUUN3ME2xPVEvPjl7IN88US=> NECx[INUSU6JRWK=
NCI-H2107 NETpV|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfW[3hKSzVyPUG5N{44OzlizszN Mn;0V2FPT0WU
SK-PN-DW NH;KT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrtbW5yUUN3ME2xPVQvPzF7IN88US=> NFHK[mtUSU6JRWK=
MC-CAR MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTNTYdPUUN3ME2yNFIvOjV|IN88US=> NXrocHoyW0GQR1XS
SNB75 M3K2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\TUWFPUUN3ME2yNlEvQTRizszN NVjlT2p2W0GQR1XS
ES4 NGHPTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3THTmlEPTB;MkKzMlc5OyEQvF2= NGrh[4pUSU6JRWK=
KARPAS-422 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ{OD6zOVIh|ryP MV7TRW5ITVJ?
NCI-H1648 NF\VXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJ{OT60PFkh|ryP M1r1eXNCVkeHUh?=
ES6 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTzSplKSzVyPUKzPU41OyEQvF2= MVTTRW5ITVJ?
KNS-81-FD NHj6N3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTNTWM2OD1{NEGuNVk4KM7:TR?= M1\ycHNCVkeHUh?=
JAR MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW4TWM2OD1{NU[uNlI2KM7:TR?= Ml7DV2FPT0WU
NB1 NHHLRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvETWM2OD1{NkCuOVE3KM7:TR?= M1vrWnNCVkeHUh?=
D-336MG NHzxdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKxTWM2OD1{NkCuOlk5KM7:TR?= NFX4SGZUSU6JRWK=
BC-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DqNWlEPTB;Mk[1MlE4QCEQvF2= M{\wPXNCVkeHUh?=
HCC2218 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSzTWM2OD1{Nk[uOFE2KM7:TR?= MofhV2FPT0WU
TE-9 Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ4Nj62Nlch|ryP NVjmfmk2W0GQR1XS
LB1047-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHzcldwUUN3ME2yOlYvPzV|IN88US=> MXLTRW5ITVJ?
CTB-1 NYLh[Y5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\HVGlEPTB;Mk[5Mlk4OyEQvF2= M1vDZ3NCVkeHUh?=
NB7 NVq1TG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v2bGlEPTB;MkexJO69VQ>? MoHMV2FPT0WU
ST486 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn5TWM2OD1{N{euOFEzKM7:TR?= NGL3eVhUSU6JRWK=
HCC1187 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrJTWM2OD1{OEKuPFEyKM7:TR?= NWnGRmZKW0GQR1XS
NCI-SNU-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml31TWM2OD1{OESuNlQ5KM7:TR?= MYLTRW5ITVJ?
COR-L279 M33McGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fPTmlEPTB;MkmxMlU5PCEQvF2= NVWxRoZWW0GQR1XS
ES8 NXjWWZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ7ND6xPFIh|ryP MlT4V2FPT0WU
U-698-M NHjMXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HCTmlEPTB;Mkm4MlI1OyEQvF2= NYLUVZVJW0GQR1XS
HEL M1ywUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vuN2lEPTB;M{C5MlE1QSEQvF2= NVzlT3pLW0GQR1XS
KINGS-1 NVHTTmU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDKRmNKSzVyPUOxNE43PzRizszN M1HybHNCVkeHUh?=
KY821 M4G3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjmTWM2OD1|M{[uOVk2KM7:TR?= NGnoemVUSU6JRWK=
MZ1-PC NFi0V2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnwTWM2OD1|NEWuOlE5KM7:TR?= MYXTRW5ITVJ?
LS-411N NYX4TmNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX4N3B1UUN3ME2zOVQvPjZizszN MlvFV2FPT0WU
SIG-M5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r4emlEPTB;M{W5Mlc5OiEQvF2= NVfpWWdGW0GQR1XS
HT Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK1TWM2OD1|NkeuO|EyKM7:TR?= MkW3V2FPT0WU
HC-1 NXvWdpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDqTWM2OD1|NkeuO|g4KM7:TR?= NGK5dWFUSU6JRWK=
NCI-H1694 NYT0bow6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;jTWM2OD1|N{KuPVM1KM7:TR?= MVrTRW5ITVJ?
BB65-RCC MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDkdWdsUUN3ME2zO|YvOjR3IN88US=> NVi2ZW1HW0GQR1XS
HAL-01 NUjUNGNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7kTWM2OD1|N{muPFM5KM7:TR?= NUnv[Xl7W0GQR1XS
ARH-77 MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTN7ND6wNFgh|ryP NGTsS3dUSU6JRWK=
MZ7-mel NXvR[|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke5TWM2OD1|OUeuNlM{KM7:TR?= MWTTRW5ITVJ?
SIMA NUPDeW1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf2TWM2OD12MEOuPVM{KM7:TR?= NWj3UGw5W0GQR1XS
DG-75 NGPZSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rmfmlEPTB;NEG1MlY6QCEQvF2= M2DRbXNCVkeHUh?=
HUTU-80 NUD3S2c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i3SGlEPTB;NEG5MlE5PSEQvF2= MWTTRW5ITVJ?
KNS-42 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDPTWM2OD12MkWuPFE2KM7:TR?= MkflV2FPT0WU
SH-4 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKyTWM2OD12MkeuOVY2KM7:TR?= NIf2WHNUSU6JRWK=
L-540 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jacmlEPTB;NEOxMlA{OSEQvF2= M4mwdnNCVkeHUh?=
NB10 NELtTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7STWM2OD12NEGuNlM1KM7:TR?= NIr2UmxUSU6JRWK=
ES1 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DMNGlEPTB;NEWyMlc2OyEQvF2= MXnTRW5ITVJ?
KMOE-2 NYLMTJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjnephKSzVyPUS1Ok44OTFizszN M2PQV3NCVkeHUh?=
MC116 M2HiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7NTWM2OD12NUiuNVE3KM7:TR?= M1fYPXNCVkeHUh?=
RCC10RGB MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzGeVRKSzVyPUS2NE4xODVizszN NWP0cYdlW0GQR1XS
RL95-2 NIT5VpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;STWM2OD12NkCuNlM4KM7:TR?= M1nwbHNCVkeHUh?=
Raji M4ToN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR4OD6xOFMh|ryP NV\4Ono2W0GQR1XS
CAS-1 NYnmTXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37ZfWlEPTB;NEeyMlA4OyEQvF2= M3H6bnNCVkeHUh?=
Calu-6 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17rWWlEPTB;NEe1MlI3PSEQvF2= MWnTRW5ITVJ?
KG-1 M4\QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXw[2l6UUN3ME20O|gvPDRizszN MV;TRW5ITVJ?
LB771-HNC NXmzW3FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR6Mj6yN|Ih|ryP NFzafVhUSU6JRWK=
ACN MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ITWM2OD12OUOuOVk6KM7:TR?= MYfTRW5ITVJ?
KM12 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHXTWM2OD12OU[uOVg6KM7:TR?= M3jxWHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 Cyclopamine 每天按50 mg/kg剂量处理小鼠,持续22天,消除HUCCT1移植瘤,且没有明显副作用。[2] Cyclopamine 按1.2 mg剂量处理Panc 05.04和 L3.6sl驱动的肿瘤7天,前者诱导明显的肿瘤细胞凋亡,后者降低肿瘤质量,降低达50-60%,但是作用于BxPC3-SMOlow肿瘤没有效果。[3] Cyclopamine单独处理E3LZ10.7 和L3.6pl移植瘤,显著抑制肿瘤转移,且和 Gemcitabine联用处理,完全废除转移。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶实验:

Gli-Luc实验测定Hh 信号通路末期, 即使用荧光素酶进行读数,测定Gli的转录调控。Cyclopamine 在DMSO中连续稀释用于实验,然后加到空的实验板上。TM3Hh12 细胞(TM3 细胞含Hh反应受体基因结构 pTA-8xGli-Luc) 悬浮在含5% FBS 和15 mM Hepes pH 7.3的F12 Ham’s/DMEM (1:1)培养基上, 加到实验板上,与Cyclopamine在37oC下温育30分钟左右。1 nM Hh-Ag 1.5 加到实验板上,然后在37oC下温育。48小时后,在实验板中加入Bright-Glo或MTS,然后在492 nm处测定发光度或吸光度。通过分析反应曲线,使用R统计软件包测定IC50值。
细胞实验:[2]
+ 展开
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, 和HCT116
  • Concentrations: 溶于DMSO, 终浓度为3 μM
  • Incubation Time: 4天
  • Method: 在96孔板上,用Cyclopamine 处理细胞。通过MTS实验测定细胞活力。进行CellTiter96比色测定,进行2和4天,然后在490 nm处通过测定光密度而测定存活细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下注射HUCCT1细胞的无胸腺裸鼠
  • Formulation: 溶于DMSO, 然后用盐水稀释
  • Dosages: 50 mg/kg/day
  • Administration: 皮下注射处理
    (Only for Reference)

溶解度 (25°C)

体外 DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 411.62
化学式

C27H41NO2

CAS号 4449-51-8
稳定性 powder
in solvent
别名 11-deoxojervine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo use in mice?

  • 回答:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品

Tags: 购买Cyclopamine | Cyclopamine供应商 | 采购Cyclopamine | Cyclopamine价格 | Cyclopamine生产 | 订购Cyclopamine | Cyclopamine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID